[HTML][HTML] Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson, L Bacal… - Allergy, Asthma & …, 2014 - Springer
Background Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
[引用][C] Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson, L Bacal… - Allergy, Asthma & …, 2014 - cir.nii.ac.jp
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple
foods using Omalizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
foods using Omalizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson, L Bacal… - Allergy, Asthma, and …, 2014 - hero.epa.gov
BACKGROUND: Up to 30% of patients with food allergies have clinical reactivity to more
than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is …
than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is …
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson… - Allergy, Asthma and …, 2014 - pure.johnshopkins.edu
Background: Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson… - Allergy, Asthma and …, 2014 - jhu.pure.elsevier.com
Background: Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson… - … : official journal of …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab.
P Bégin, T Dominguez, SP Wilson, L Bacal… - Allergy, Asthma, and …, 2014 - europepmc.org
Background Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bngin, T Dominguez, SP Wilson, L Bacal… - Allergy, Asthma & …, 2014 - go.gale.com
Background Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
[HTML][HTML] Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez… - Allergy, Asthma …, 2014 - aacijournal.biomedcentral.com
Up to 30% of patients with food allergies have clinical reactivity to more than one food
allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
[PDF][PDF] Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
P Bégin, T Dominguez, SP Wilson, L Bacal, A Mehrotra… - 2014 - researchgate.net
Background: Up to 30% of patients with food allergies have clinical reactivity to more than
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …
one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under …